Regression of neovascular iris vessels by intravitreal injection of bevacizumab

Retina. 2006 Sep;26(7):839-41. doi: 10.1097/01.iae.0000230425.31296.3b.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Anterior Eye Segment / blood supply
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Female
  • Glaucoma, Neovascular / drug therapy*
  • Humans
  • Injections
  • Intraocular Pressure
  • Iris / blood supply*
  • Male
  • Middle Aged
  • Neovascularization, Pathologic / drug therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab